



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

5 β -Dihydrocortisol-d6

Cat. No.:	HY-N3995S
Molecular Formula:	C ₂₁ H ₂₆ D ₆ O ₅
Molecular Weight:	370.51
Target:	Apoptosis; Drug Metabolite
Pathway:	Apoptosis; Metabolic Enzyme/Protease
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	5 β -Dihydrocortisol-d6 is the deuterium labeled 5 β -Dihydrocortisol. 5 β -Dihydrocortisol, a metabolite of Cortisol, is a potential mineralocorticoid. 5 β -Dihydrocortisol can potentiate glucocorticoid activity in raising the intraocular pressure. 5 β -Dihydrocortisol causes breast cancer cell apoptosis ^{[1][2][3][4][5]} .
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.
- [2]. Marver D, et al. Dihydrocortisol: a potential mineralocorticoid. *J Steroid Biochem.* 1978 Jan;9(1):1-7.
- [3]. Kallubai M, et al. Spectroscopic evaluation of synthesized 5 β -dihydrocortisol and 5 β -dihydrocortisol acetate binding mechanism with human serum albumin and their role in anticancer activity. *J Biomol Struct Dyn.* 2019 Feb;37(3):623-640.
- [4]. Southren AL, et al. 5 beta-Dihydrocortisol: possible mediator of the ocular hypertension in glaucoma. *Invest Ophthalmol Vis Sci.* 1985 Mar;26(3):393-5.
- [5]. Appanna N, et al. Differential activity and expression of human 5 β -reductase (AKR1D1) splice variants. *J Mol Endocrinol.* 2021 Mar;66(3):181-194.
- [6]. Weinstein BI, et al. Potentiation of glucocorticoid activity by 5 beta-dihydrocortisol: its role in glaucoma. *Science.* 1983 Oct 14;222(4620):172-3.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA